Jack A Cipolla1, Hong Jiang, Ava-Gaye Y Simms

  • 1University of Miami Miller School of Medicine (JAC, HJ, A-GYS, BB, TR, JW), Miami, Florida; Department of Ophthalmology (HJ, A-GYS, JW), Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida; Department of Neurology (HJ, BB, TR), University of Miami Miller School of Medicine, Miami, Florida; and The University of Miami Evelyn F. McKnight Brain Institute (HJ, TR, JW), Miami, Florida.

概括

阿尔茨海默病 (AD) 患者表现出视网膜毛细管功能 (RCF) 损伤,这是大脑血流问题的潜在指标. 这项研究显示,与健康对照人群相比,AD患者的RCF显著降低.

相关概念视频

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
6.1K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219